CanSino Biologics slumps by a record 20 per cent in Hong Kong, leading losses among Chinese peers after Biden’s team backs waiving patent and other rights on Covid-19 vaccines. The move undermines profit outlook, an investor says. Read More
CanSino Biologics slumps by a record 20 per cent in Hong Kong, leading losses among Chinese peers after Biden’s team backs waiving patent and other rights on Covid-19 vaccines. The move undermines profit outlook, an investor says. Read More
